Department of Ultrasound, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Laboratory of Ultrasound Medicine, West China Hospital, Sichuan University, Chengdu, China.
Int J Hyperthermia. 2023;40(1):2174709. doi: 10.1080/02656736.2023.2174709.
Radiofrequency ablation (RFA) is a first-line treatment for early-stage hepatocellular carcinoma (HCC). However, the recurrence after RFA remains an urgent challenge. Current studies have shown that residual tumor after RFA is an important cause of recurrence.
We hypothesized that the products of dead tumor cells after RFA have direct effects on the development of residual tumors. Further, we investigated the underlying mechanisms.
The proliferation and invasion ability of HepG2 and Huh7 cells were assessed using CCK-8, colony formation, EdU, transwell invasion and migration assay. Immunofluorescence and western blotting were used to show HMGB1 released from dead tumor cells. The levels of MMP2, MMP9, CyclinE1 and pERK1/2 were determined using western blotting. Finally, validation was performed in BALB/c nude mice xenograft tumor models.
The products of dead tumor cells after thermal treatment can promote the proliferation and invasion of residual HCC cells. Dead tumor cells could release high-mobility group box 1 (HMGB1) after thermal treatment. Similar to the products of dead tumor cells, the recombinant protein of HMGB1 can promote the proliferation and invasion of residual HCC cells. Moreover, HMGB1 could bind to receptor of advanced glycation end-products. Then, it activated the ERK1/2 pathway and significantly upregulated the expressions of MMP2, MMP9, and CyclinE1.
Our study reveals that HMGB1 released by dead tumor cells after thermal treatment can promote the proliferation and invasion of residual HCC cells. Hence, the HMGB1/RAGE/ERK1/2 pathway is a potential target for improving the prognosis of HCC after radiofrequency ablation.
射频消融(RFA)是治疗早期肝细胞癌(HCC)的一线治疗方法。然而,RFA 后的复发仍然是一个紧迫的挑战。目前的研究表明,RFA 后残留肿瘤是复发的重要原因。
我们假设 RFA 后死亡的肿瘤细胞产物对残留肿瘤的发展有直接影响。进一步研究其潜在机制。
使用 CCK-8、集落形成、EdU、Transwell 侵袭和迁移实验评估 HepG2 和 Huh7 细胞的增殖和侵袭能力。免疫荧光和 Western blot 用于显示死肿瘤细胞释放的高迁移率族蛋白 B1(HMGB1)。Western blot 用于测定 MMP2、MMP9、CyclinE1 和 pERK1/2 的水平。最后,在 BALB/c 裸鼠异种移植肿瘤模型中进行验证。
热疗后死亡肿瘤细胞的产物可促进残余 HCC 细胞的增殖和侵袭。热疗后死肿瘤细胞可释放高迁移率族蛋白 B1(HMGB1)。与死肿瘤细胞的产物类似,HMGB1 的重组蛋白可促进残余 HCC 细胞的增殖和侵袭。此外,HMGB1 可与晚期糖基化终产物受体结合。然后,它激活 ERK1/2 通路,并显著上调 MMP2、MMP9 和 CyclinE1 的表达。
我们的研究表明,热疗后死亡肿瘤细胞释放的 HMGB1 可促进残余 HCC 细胞的增殖和侵袭。因此,HMGB1/RAGE/ERK1/2 通路是改善射频消融后 HCC 预后的潜在靶点。